Just as AI is substantially escalating privacy risks, we're headed in the wrong direction when it comes to resourcing privacy ...
AstraZeneca’s tozorakimab meets primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD: Cambridge, UK Saturday, March 28, 2026, 11:00 Hrs [IST] Posit ...
Humans have long dreamed of a cure-all.Subscribe to The Post Most newsletter for the most important and interesting stories ...
Local schools will lose nearly $5 million in annual levy match dollars.
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer baseCompleted enrollment in FDA-mandated ...
Viomi Technology Co., Ltd ('Viomi” or the 'Company”) (NASDAQ: VIOT), a leading technology company for home water solutions in ...
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 ...
For decades, the economics of plastics have been deceptively simple: virgin resin-derived from oil and gas-has been cheaper, more reliable, and easier to scale than recycled alternatives. Recycling, ...
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafterCash and cash ...
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary ...
HONG KONG, HK / ACCESS Newswire / March 27, 2026 / SouthGobi Resources Ltd. (Hong Kong Stock Exchange ("HKEX"): 1878, TSX ...
Journey Medical Corporation ( DERM) Q4 2025 Earnings Call March 25, 2026 4:30 PM EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results